AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma
Open Access
- 30 August 2025
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (1) , 257-268
Abstract
Aims: Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a novel JAK1 selective inhibitor, following inhaled (dry powder, nebulized) and intravenous administration to healthy participants and patients with mild asthma. Methods: This was a randomized, single‐blind, placebo‐controlled Phase 1 study (NCT03766399) of single‐ and multiple‐ascending doses conducted using a three‐part design. Healthy participants and patients with mild asthma aged 18–55 years were recruited. The study evaluated safety, tolerability, PK and PD of AZD0449. PD was measured as the effect on fractional exhaled nitric oxide (FeNO). Systemic target engagement was measured using phosphorylation of signal transducer and activator of transcription 6 (pSTAT6). Results: A total of 125 participants were included in the study. No drug‐related safety concerns emerged. Following inhaled administration, AZD0449 showed low, dose‐proportional, systemic exposures and elimination from plasma was partly absorption‐limited, suggesting lung retention and supporting once‐daily dosing. At the dose levels evaluated (1.2–5.0 mg), there was no significant anti‐inflammatory effect (reduction in FeNO) with AZD0449 vs . placebo, following repeated dosing for 14 days. Furthermore, there was no significant suppression of pSTAT6. Conclusions: AZD0449 was safely administered via inhalation, with low systemic exposure and lung retention. This study provides a greater understanding of inhaled dosing of small molecule JAK1 inhibitors for the treatment of asthma. No effect on PD biomarkers (FeNO and STAT6) was observed.Keywords
Funding Information
- National Institute for Health Research
- Manchester Biomedical Research Centre
- AstraZeneca
This publication has 25 references indexed in Scilit:
- Diagnostic accuracy of FeNO in asthma and predictive value for inhaled corticosteroid responsiveness: A prospective, multicentre studyeClinicalMedicine, 2022
- Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammationPulmonary Pharmacology & Therapeutics, 2022
- JAK inhibitors for asthmaJournal of Allergy and Clinical Immunology, 2021
- Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trialJournal of Allergy and Clinical Immunology, 2021
- Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthmaBioorganic & Medicinal Chemistry Letters, 2019
- Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942EBioMedicine, 2018
- Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled DrugsCPT: Pharmacometrics & Systems Pharmacology, 2016
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseCurrent Opinion in Pharmacology, 2012
- Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7–induced signalingProceedings of the National Academy of Sciences, 2010
- Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC)Thorax, 2007